Keyword: Seqirus

Seqirus plans to add cell-based and adjuvanted flu vaccine capacity in a $140 million expansion to its plant in Holly Springs, North Carolina.

Here is some other vaccine news of note for the week.

While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.

Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.

A group of pediatric experts has recommended injected vaccines over AstraZeneca's FluMist for the upcoming season.

CSL's flu vaccine unit Seqirus posted $1.09 billion in sales during its 2018 fiscal year and turned in its first-ever profit.

Seqirus expects to offer 50 million flu vaccine doses, while GSK plans to boost its supplies to 40 million to 45 million, its highest total ever.